Views: 1,416 | Downloads:
217
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Detection of PTEN Immunoreactivity in Endometrial Hyperplasia and Adenocarcinoma
Tantbirojn P 
,
Triratanachat S ,
Trivijitsilp P ,
Niruthisard S
,
Triratanachat S ,
Trivijitsilp P ,
Niruthisard S Objective: To investigate PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression in
endometrial hyperplasia and adenocarcinoma as analyzed by immunohistochemistry.
Material and Method: PTEN protein expression was evaluated by immunohistrochemical study of 70 paraffinembedded
curettage endometrial tissue samples (10 normal endometrium, 55 endometrial hyperplasia, and
15 endometrial adenocarcinomas) selected from surgical pathology files of the Division of Gynecologic
Pathology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, from
2001 to 2004. Intensity of epithelial staining of PTEN immunoreactivity in different histologic types was
determined.
Results: Absence of PTEN protein expression was detected in 60% of endometrial carcinoma, 60% of atypical
endometrial hyperplasia, and 24% of typical endometrial hyperplasia. In endometrial hyperplasia without
atypia group, the majority of cases revealed moderate to strong PTEN expression, with 70% in simple hyperplasia
and 47% in complex hyperplasia. There is a significant statistical difference of PTEN immunoreactivity
among proliferative endometrium, endometrial hyperplasia and endometrial carcinoma group (p = 0.004).
Conclusion: Complete loss of PTEN protein expression was most commonly found in endometrial carcinoma
and hyperplasia with cytologic atypia.
Keywords: PTEN, Endometrial hyperplasia, Endometrial carcinoma
endometrial hyperplasia and adenocarcinoma as analyzed by immunohistochemistry.
Material and Method: PTEN protein expression was evaluated by immunohistrochemical study of 70 paraffinembedded
curettage endometrial tissue samples (10 normal endometrium, 55 endometrial hyperplasia, and
15 endometrial adenocarcinomas) selected from surgical pathology files of the Division of Gynecologic
Pathology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, from
2001 to 2004. Intensity of epithelial staining of PTEN immunoreactivity in different histologic types was
determined.
Results: Absence of PTEN protein expression was detected in 60% of endometrial carcinoma, 60% of atypical
endometrial hyperplasia, and 24% of typical endometrial hyperplasia. In endometrial hyperplasia without
atypia group, the majority of cases revealed moderate to strong PTEN expression, with 70% in simple hyperplasia
and 47% in complex hyperplasia. There is a significant statistical difference of PTEN immunoreactivity
among proliferative endometrium, endometrial hyperplasia and endometrial carcinoma group (p = 0.004).
Conclusion: Complete loss of PTEN protein expression was most commonly found in endometrial carcinoma
and hyperplasia with cytologic atypia.
Keywords: PTEN, Endometrial hyperplasia, Endometrial carcinoma
Download:
PDF